BioStem Technologies to Showcase Perinatal Tissue Platform at TD Cowen Healthcare Conference

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

BioStem Technologies will present its perinatal tissue-based wound care platform at the TD Cowen Healthcare Conference on March 2, 2026, in Boston.

BioStem Technologies to Showcase Perinatal Tissue Platform at TD Cowen Healthcare Conference

BioStem Technologies (OTC: BSEM), a medical device company focused on advanced wound care solutions derived from perinatal tissue, will present at the 46th Annual TD Cowen Healthcare Conference scheduled for March 2, 2026, in Boston. The presentation will provide an opportunity for investors and healthcare industry professionals to learn about the company's product portfolio and strategic initiatives.

Investors and stakeholders interested in attending the presentation remotely will have access to live and archived webcasts through BioStem's investor relations website. This appearance aligns with the company's ongoing efforts to engage with the investment community and present its position within the competitive wound care and regenerative medicine markets.

The TD Cowen Healthcare Conference is a prominent industry gathering that attracts institutional investors, healthcare professionals, and company executives seeking to discuss emerging trends and developments in the healthcare sector.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 20

Related Coverage

Benzinga

Relativity Acquisition Shareholders OK SPAC Merger with Stem Cell Pioneer Instinct Bio

Relativity Acquisition shareholders approve SPAC merger with stem cell company Instinct Bio Technical, enabling Nasdaq listing under $BIOT and $BIOTW expected within weeks.

ACQC
GlobeNewswire Inc.

Relativity Acquisition Corp. Shareholders Greenlight SPAC Merger with Instinct Bio

Relativity Acquisition Corp. shareholders approved merger with stem cell firm Instinct Bio Technical Company Inc. Combined entity to trade on Nasdaq as $BIOT and $BIOTW.

ACQC
Benzinga

Avaí Bio Advances Anti-Aging Therapy With Klotho Protein Cloning Milestone

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.

VRTXCRSPAVAI
GlobeNewswire Inc.

Law Firm Launches Securities Fraud Investigations Into Four Public Companies

Law firm investigates securities fraud claims against ASP Isotopes, Integer Holdings, Molina Healthcare, and Soleno Therapeutics for alleged misstatements regarding technology, competitive position, medical costs, and drug safety.

ASPIITGRMOH
The Motley Fool

Tenon Medical Doubles Q4 Revenue on FDA Clearance, Eyes Aggressive 2026 Expansion

Tenon Medical reports 92% Q4 revenue growth to $1.5M, achieves 69% gross margins, secures FDA clearance and $4.3M financing for spine fusion device expansion.

TNONTNONW
Benzinga

Embecta Expands Drug-Delivery Portfolio With $200M Owen Mumford Acquisition

Embecta to acquire UK firm Owen Mumford for up to $200M, bolstering drug-delivery capabilities and chronic care market reach. Stock rises 4.63%.

EMBC